Lixte Biotechnology

What Lixte Biotechnology does

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a publicly traded Delaware-incorporated clinical-stage pharmaceutical company that, until mid-2026, focused exclusively on developing a novel class of cancer therapeutics based on inhibition of Protein Phosphatase 2A (PP2A). Its lead asset, LB-100, is a first-in-class small-molecule PP2A inhibitor designed to enhance the efficacy of existing chemotherapy and immunotherapy by stimulating cell cycle progression, inhibiting DNA repair, enhancing T cell proliferation, increasing cytokine release, and promoting neoantigen production. LB-100 is being evaluated in Phase 1/2 clinical collaborations with MD Anderson Cancer Center, GSK (using dostarlimab), and Northwestern University's Lurie Cancer Center across ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma indications. In November 2025 the company acquired UK-based Liora Technologies Europe Ltd., adding the LiGHT System, a proprietary electronically controlled proton therapy platform installed at Daresbury Laboratory in the UK.

In June 2026 the company announced a strategic transformation: a definitive agreement to acquire 100% of NOMAD Transportable Power Systems, Inc.—a Vermont-based market leader in mobile, utility-grade 1 MW battery energy storage systems (BESS)—with plans to rename itself NOMAD Power Solutions upon closing (expected on or about July 1, 2026). The company will simultaneously seek a strategic partner for its legacy pharmaceutical and med-tech operations. NOMAD's product line targets utilities, industrial operators, government agencies, and hyperscale AI data centers, and benefits from UL 9540 full-system validation and a deployable equipment classification that bypasses the 2–5 year permitting timelines associated with permanent energy infrastructure. A $16.6 million registered direct offering closed June 3, 2026 to fund the transformation, on top of approximately $11 million raised through 2025 registered direct offerings and private placements.

The company's business model has been entirely pre-revenue on the pharmaceutical side, generating no product revenue and reporting recurring net losses (approximately -$3.6 million in the most recent reported period). Revenue mechanics going forward will shift toward direct equipment sales, rentals, and potential service contracts for mobile BESS, supplemented by any retained royalty or licensing arrangements from the legacy LB-100 and LiGHT programs. Go-to-market is sales-led via clinical trial sites (pharma) and direct enterprise sales to utilities and data center customers (NOMAD), with pricing not publicly disclosed. Headcount is small (1–10 employees) and the company is led by Chairman/CEO Geordan Pursglove (appointed June 2025), with Stuart D. Porter (Founder/CEO of Denham Capital Management) joining the board effective May 29, 2026.

Name

Lixte Biotechnology

Legal name

LIXTE Biotechnology Holdings, Inc.

Website

https://lixte.com

Company type

Public

Founded year

2005

Operating status

Operating

Headcount range

1–10 employees

Short description

Lixte Biotechnology is a clinical-stage pharmaceutical company developing first-in-class PP2A inhibitor LB-100 for cancer treatment, now pivoting to become NOMAD Power Solutions, an AI energy infrastructure platform via its pending acquisition of mobile utility-grade battery storage leader NOMAD Transportable Power Systems.

Ownership category

akta.pro rank

Product category

Clinical-Stage Oncology Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411), Computer and Peripheral Equipment Manufacturing (3341)

SIC

Pharmaceutical Preparations (2834), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Wholesale-Computers & Peripheral Equipment & Software (5045)

akta.pro primary industry

Laboratory Informatics for Diagnostics (LIS/Middleware/Analyzer Connectivity) (HLAHAAAO)

akta.pro secondary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• PP2A inhibitors
• Cancer immunotherapy enhancement
• Clinical-stage oncology
• Proton therapy systems
• Battery energy storage

Headquarters

HQ city

East Setauket

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Clinical-stage pharmaceutical development: Pre-revenue clinical-stage company developing PP2A inhibitor LB-100 and proton therapy systems. No commercial products yet. Generating revenue through potential licensing deals, partnership agreements, and eventual commercial launches.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company developing LB-100, a first-in-class protein phosphatase 2A (PP2A) inhibitor intended to enhance the efficacy of chemotherapy and immunotherapy in solid tumors. The company also operates the LiGHT System proton therapy platform (acquired via Liora Technologies Europe Ltd.) and is acquiring NOMAD Transportable Power Systems to add mobile utility-grade battery energy storage for the AI data-center market.

Product overview

Lixte Biotechnology Holdings is a clinical-stage pharmaceutical and med-tech company that has undergone significant transformation. The company's core product is LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy efficacy across multiple cancer types (ovarian, lung, colon, sarcoma). In November 2025, LIXTE acquired Liora Technologies Europe Ltd., adding the LiGHT System—electronically controlled proton therapy technology for high-precision cancer treatment. As of mid-2026, the company announced a strategic pivot toward AI energy infrastructure through the pending acquisition of NOMAD Transportable Power Systems, a mobile utility-grade battery energy storage company, with plans to rename the combined entity NOMAD Power Solutions.

Differentiator

Problem solved

Functional benefit

Products and services

• LB-100 First-in-class small-molecule protein phosphatase 2A (PP2A) inhibitor designed to enhance the efficacy of chemotherapy and immunotherapy in solid tumors such as ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma; currently in Phase 1/2 trials including a combination trial with GSK's dostarlimab at MD Anderson Cancer Center expanded to 42 patients.
• LiGHT System Proprietary electronically controlled proton therapy system for high-precision cancer treatment that delivers proton beams stopping at precise depths to reduce collateral damage to healthy tissue; brought into LIXTE through its wholly owned subsidiary Liora Technologies Europe Ltd.
• NOMAD Transportable Battery Energy Storage System Mobile, utility-grade 1 MW battery energy storage system (BESS) targeted at utilities, data centers, industrial operators, and government agencies, designed to bypass 2-5 year permitting and interconnection timelines by deploying as equipment rather than permanent infrastructure; the first mobile utility-grade 1 MW BESS brought to market with UL 9540 full-system validation.

Quantifiable outcome

• LB-100 demonstrated favorable safety profile in Phase 1 clinical trials at doses associated with anti-cancer activity
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• NOMAD Transportable Power SystemscoreStrategic or Co-development Partner · 12 June 2026Definitive agreement to acquire 100% of NOMAD, the market leader in deployable utility-grade battery energy storage. Upon closing, company will be renamed NOMAD Power Solutions. Transaction expected to close July 1, 2026.
• Liora TechnologiescoreStrategic or Co-development Partner · 27 March 2026Strategic partnership integrating multimodal oncology data using foundation model-based embeddings, unifying clinical text, radiology scans, pathology images, and molecular profiles for precision-guided patient care.
• Northwestern University Lurie Cancer CenterminorStrategic or Co-development Partner · 1 January 2025Additional clinical trial site for LB-100 studies, expanding the company's clinical trial network.
• MD Anderson Cancer CentercoreStrategic or Co-development Partner · 1 January 2024Clinical trial collaboration for LB-100 in combination with GSK's dostarlimab for ovarian clear cell cancer. Trial expanded from 21 to 42 patients following favorable safety data. Initial findings expected in first half of 2026.
• GSKcoreStrategic or Co-development Partner · 1 January 2024Clinical collaboration providing dostarlimab (anti-PD-1 therapy) for combination trial with LB-100. The combination leverages LB-100's PP2A inhibition to enhance immunotherapy response.

Scale indicators17 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• MEI Pharma: Clinical-stage small-molecule oncology developer with comparable size and pipeline-stage profile; relevant comparable for capital-markets dynamics and clinical-trial execution in micro-cap oncology.
• Enchanted Rock: Deployable natural gas and battery energy storage provider serving utilities and commercial customers with on-demand behind-the-meter solutions; directly comparable business model to the NOMAD mobile utility-grade BESS business Lixte is acquiring.
• Cardiff Oncology: Public clinical-stage oncology company focused on small-molecule drug development with similar partnership-driven clinical execution model and minimal commercial revenue.
• Aprea Therapeutics: Small-cap clinical-stage oncology company developing small-molecule therapeutics, analogous in scale and stage to Lixte's LB-100 program and provides a directly comparable reference for valuation and clinical-de-risking trajectory.
• CASI Pharmaceuticals: Small-cap oncology company with a clinical pipeline and capital-raising profile similar to Lixte, useful as a direct peer on financial structure and investor base dynamics.

Broad incumbents

• IBA (Ion Beam Applications): Global leader in proton therapy and particle accelerator systems with a broad commercial installed base; benchmarks the med-tech scale Lixte's LiGHT subsidiary would need to reach.
• Mevion Medical Systems: Established proton therapy systems manufacturer with multiple FDA-cleared compact proton therapy platforms; directly comparable to the Liora Technologies LiGHT System business in Lixte's med-tech portfolio.
• Fluence Energy: Public global leader in utility-scale battery energy storage systems with broad product portfolio; relevant scaled comparable for the BESS market opportunity Lixte is repositioning into via NOMAD.

Emerging players

• Tragara Pharmaceuticals: Clinical-stage oncology company also targeting protein phosphatase pathways; closest peer for LB-100's PP2A mechanism-of-action competitive context.
• Iterion Therapeutics: Emerging clinical-stage oncology company developing targeted therapies with comparable mechanism-of-action challenges and small-cap structure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/LixteBiotech
• YouTubeyoutube.com/@LIXTEBiotechnology
• Facebookfacebook.com/LixteBiotechnology
• LinkedInlinkedin.com/company/lixte-biotechnology-holdings-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds9 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lixte Biotechnology